Russia registers fluorothiazinone, domestic drug for treatment of bacterial infections

Russia has registered a new domestic drug, fluorothiazinone, which is intended for the treatment of bacterial infections caused by microorganisms resistant to antibiotics, reports The Pharma Letter’s local correspondent.

The drug could go on sale in about three months, however, according to experts, there is still too little information about the mechanism of its action and there is a need to wait for clinical recommendations.

According to the Russian Ministry of Health, fluorothiazinone, is a full-cycle drug, which was developed and produced by the Gamaleya Research Center of Epidemiology and Microbiology, which was behind the development of Sputnik V, one of the first COVID-19 vaccines.